Payment overview · 2025
General Payments
$73.94
4 reported records · 4 companies
Healthcare provider profile · identity verified
Curtis D Stokes, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WALTERBORO, SC · NPI 1396784369
Verified facts
What the public records show
CMS Open Payments records show Curtis D Stokes, M.D. received $73.94 in general payments during 2025 across 4 reported records.
Novo Nordisk Inc accounted for 35.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.96 | 35.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.54 | 23.7% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $16.60 | 22.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.84 | 18.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $73.94 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.96 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.54 | 1 | 2025 |
Source payment records
|
|||||
| FABRAZYME Normalized: fabrazyme |
Biological | GENZYME CORPORATION | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.84 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 134 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
65 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
37 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
134 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
28 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 682 | 205 |
| Atorvastatin Calcium | Atorvastatin Calcium | 551 | 160 |
| Metoprolol Succinate | Metoprolol Succinate | 341 | 96 |
| Prednisone | Prednisone | 334 | 228 |
| Gabapentin | Gabapentin | 330 | 92 |
| Omeprazole | Omeprazole | 275 | 79 |
| Furosemide | Furosemide | 256 | 82 |
| Hydrochlorothiazide | Hydrochlorothiazide | 251 | 78 |
| Metformin Hcl | Metformin Hcl | 249 | 72 |
| Naproxen | Naproxen | 242 | 101 |
| Losartan Potassium | Losartan Potassium | 228 | 65 |
| Diclofenac Sodium | Diclofenac Sodium | 220 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 219 | 105 |
| Lisinopril | Lisinopril | 194 | 56 |
| Famotidine | Famotidine | 180 | 50 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 178 | 50 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 173 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 162 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 159 | 39 |
| Amoxicillin | Amoxicillin | 147 | 131 |
| Eliquis | Apixaban | 134 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 128 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 127 | 33 |
| Montelukast Sodium | Montelukast Sodium | 118 | 32 |
| Spironolactone | Spironolactone | 107 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 29 |
| Trazodone Hcl | Trazodone Hcl | 105 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 101 | 29 |
| Meloxicam | Meloxicam | 100 | 28 |
| Tramadol Hcl | Tramadol Hcl | 98 | 25 |
| Potassium Chloride | Potassium Chloride | 97 | 30 |
| Jardiance | Empagliflozin | 96 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 89 | 70 |
| Allopurinol | Allopurinol | 86 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 25 |
| Glimepiride | Glimepiride | 83 | 20 |
| Clonazepam | Clonazepam | 80 | 16 |
| Celecoxib | Celecoxib | 75 | 22 |
| Metformin Hcl Er | Metformin Hcl | 75 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 31 |
| Doxepin Hcl | Doxepin Hcl | 74 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 73 | 21 |
| Sulindac | Sulindac | 73 | 34 |
| Amitriptyline Hcl | Amitriptyline Hcl | 72 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 72 | 59 |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | 23 |
| Simvastatin | Simvastatin | 71 | 25 |
| Methocarbamol | Methocarbamol | 69 | 30 |
| Linzess | Linaclotide | 67 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 66 | 31 |
| Farxiga | Dapagliflozin Propanediol | 65 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 65 | 21 |
| Januvia | Sitagliptin Phosphate | 64 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 63 | 12 |
| Buspirone Hcl | Buspirone Hcl | 62 | 16 |
| Donepezil Hcl | Donepezil Hcl | 61 | 18 |
| Carvedilol | Carvedilol | 60 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 59 | 34 |
| Oxybutynin Chloride | Oxybutynin Chloride | 58 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 33 |
| Levetiracetam | Levetiracetam | 56 | 14 |
| Alprazolam | Alprazolam | 55 | 12 |
| Azithromycin | Azithromycin | 54 | 45 |
| Mirtazapine | Mirtazapine | 51 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 51 | 14 |
| Rybelsus | Semaglutide | 50 | 12 |
| Alendronate Sodium | Alendronate Sodium | 49 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | suppressed |
| Cephalexin | Cephalexin | 47 | 44 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 47 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 46 | 14 |
| Sertraline Hcl | Sertraline Hcl | 46 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 15 |
| Lovastatin | Lovastatin | 45 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 44 | 15 |
| Dexamethasone | Dexamethasone | 44 | 40 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 44 | 13 |
| Pregabalin | Pregabalin | 44 | 12 |
| Cefuroxime | Cefuroxime Axetil | 41 | 34 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Ozempic | Semaglutide | 40 | suppressed |
| Lorazepam | Lorazepam | 39 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 22 |
| Fluconazole | Fluconazole | 37 | 26 |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Baclofen | Baclofen | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | 11 |
| Valacyclovir | Valacyclovir Hcl | 35 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 33 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Ibuprofen | Ibuprofen | 32 | 16 |
| Chlorthalidone | Chlorthalidone | 31 | 11 |
| Meclizine Hcl | Meclizine Hcl | 31 | 18 |
| Metoclopramide Hcl | Metoclopramide Hcl | 31 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Glipizide | Glipizide | 30 | 12 |
| Atenolol | Atenolol | 29 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 29 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 27 |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 28 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Risperidone | Risperidone | 27 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Nystatin | Nystatin | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | 12 |
| Finasteride | Finasteride | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | 11 |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Colchicine | Colchicine | 19 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | 16 |
| Topiramate | Topiramate | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 17 |
| Olanzapine | Olanzapine | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Metronidazole | Metronidazole | 16 | 15 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Etodolac | Etodolac | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Tobramycin | Tobramycin | 12 | 11 |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $73.94 · 4 records | Novo Nordisk Inc | AIRSUPRA, ELIQUIS, FABRAZYME, NURTEC ODT, Ozempic | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error